Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-Current Deffered Revenue (2018 - 2022)

Historic Non-Current Deffered Revenue for Revolution Medicines (RVMD) over the last 5 years, with Q3 2022 value amounting to $5.4 million.

  • Revolution Medicines' Non-Current Deffered Revenue fell 4401.74% to $5.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was $5.4 million, marking a year-over-year decrease of 4401.74%. This contributed to the annual value of $6.6 million for FY2021, which is 2249.73% down from last year.
  • Latest data reveals that Revolution Medicines reported Non-Current Deffered Revenue of $5.4 million as of Q3 2022, which was down 4401.74% from $3.8 million recorded in Q2 2022.
  • In the past 5 years, Revolution Medicines' Non-Current Deffered Revenue ranged from a high of $14.7 million in Q4 2019 and a low of -$552000.0 during Q4 2018
  • Moreover, its 5-year median value for Non-Current Deffered Revenue was $8.1 million (2021), whereas its average is $8.0 million.
  • As far as peak fluctuations go, Revolution Medicines' Non-Current Deffered Revenue soared by 276793.48% in 2019, and later crashed by 4965.23% in 2022.
  • Quarter analysis of 5 years shows Revolution Medicines' Non-Current Deffered Revenue stood at -$552000.0 in 2018, then skyrocketed by 2767.93% to $14.7 million in 2019, then crashed by 42.41% to $8.5 million in 2020, then fell by 22.5% to $6.6 million in 2021, then fell by 17.57% to $5.4 million in 2022.
  • Its Non-Current Deffered Revenue stands at $5.4 million for Q3 2022, versus $3.8 million for Q2 2022 and $5.7 million for Q1 2022.